Gavestinel

CAS : 153436-38-5

Ref. 3D-DGA43638

Informations sur le produit

• Nom: Gavestinel
• Synonymes: 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-[(1E)-3-oxo-3-(phenylamino)-1-propen-1-yl]-, sodium salt (1:1), 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-[(1E)-3-oxo-3-(phenylamino)-1-propenyl]-, monosodium salt, 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-[3-oxo-3-(phenylamino)-1-propenyl]-, monosodium salt, (E)-, 1H-Indole-2-carboxylicacid, 4,6-dichloro-3-[3-oxo-3-(phenylamino)-1-propenyl]-, monosodium salt,(E)-, Gv 150526A

Description

Gavestinel is a novel anti-platelet agent that is undergoing clinical trials for the treatment of stroke. Gavestinel binds to and blocks the P2Y12 receptor in platelets, which inhibits platelet aggregation and prevents formation of blood clots. In addition to its anti-platelet effects, gavestinel also has been shown to protect neurons against ischemic brain damage. This protection is likely due to the inhibition of neuronal death by cation channels and protein transport, as well as an increase in the release of gamma-aminobutyric acid (GABA) from GABAergic neurons. Gavestinel also inhibits glutamate release from the presynaptic neuron, leading to less excitotoxicity at postsynaptic sites. The mechanism of action has been elucidated using kinetic data obtained from binding assays with recombinant proteins. Gavestinel is also an inhibitor of ATP channels that are found in many types of cells, including glial cells.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 397.19 g/mol
• Formule: C₁₈H₁₁Cl₂N₂NaO₃
• Degré de pureté: Min. 95%